Core Viewpoint - Sanbo Brain Science's stock closed at 50.08 yuan, up 3.58%, with a rolling PE ratio of 93.87 times and a total market capitalization of 10.316 billion yuan [1] Group 1: Company Performance - For Q1 2025, Sanbo Brain Science reported revenue of 393 million yuan, a year-on-year increase of 16.78% [1] - The net profit for the same period was 38.3136 million yuan, reflecting a year-on-year growth of 14.56% [1] - The sales gross margin stood at 26.44% [1] Group 2: Market Position - The average PE ratio for the medical services industry is 48.19 times, with a median of 59.42 times, placing Sanbo Brain Science at the 37th position in the industry ranking [1][2] - The company has one institutional holder, a fund, with a total holding of 535,900 shares valued at 2.8 million yuan [1]

Group 1 - The core viewpoint of the article highlights that Sanbo Brain Science's stock closed at 44.79 yuan, down 1.10%, with a rolling PE ratio of 83.95 times and a total market value of 9.226 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical services sector is 40.82 times, with a median of 45.93 times, placing Sanbo Brain Science at the 38th position in the industry ranking [1] - On June 5, the net outflow of main funds for Sanbo Brain Science was 23.9984 million yuan, although there was an overall inflow of 7.3365 million yuan over the past five days [1] Group 2 - Sanbo Brain Science Hospital Management Group Co., Ltd. primarily engages in clinical medical services, with its main products including medical services, pharmaceuticals, supply chain, and other businesses [1] - The latest quarterly performance report for Q1 2025 shows that the company achieved an operating income of 393 million yuan, a year-on-year increase of 16.78%, and a net profit of 38.3136 million yuan, a year-on-year increase of 14.56%, with a sales gross margin of 26.44% [1]

Group 1: Company Overview - Sanbo Brain Science has experienced a significant stock price drop, with a maximum intraday decline of over 12%, closing down 10.17% at 40.44 yuan per share, resulting in a market capitalization of 8.33 billion yuan [1] - The company reported a revenue of 1.429 billion yuan in 2024, representing a year-on-year growth of 8.84%, and a net profit attributable to shareholders of 105 million yuan, up 34.24% year-on-year [2][8] - Sanbo Brain Science's first-quarter report for 2025 showed total revenue of 393 million yuan, a year-on-year increase of 16.78%, and a net profit of 38.31 million yuan, up 14.56% year-on-year [8] Group 2: Leadership and Governance Issues - The chairman Zhang Yang was placed under investigation by the Inner Mongolia Supervisory Committee, raising concerns about potential bribery or collusion in crimes [2][4] - The company maintains that it has a robust governance structure and internal control mechanisms, asserting that the investigation will not significantly impact its daily operations [5][6] - There are questions regarding the jurisdiction of the investigation, as Sanbo Brain Science and its subsidiaries are not registered in Inner Mongolia, leading to speculation about the reasons behind the investigation [4][6] Group 3: Financial Performance and Challenges - Sanbo Brain Science's financial reports indicate a heavy reliance on its flagship hospital, with the Capital Medical University Sanbo Brain Hospital accounting for approximately 34.8% of total revenue and contributing 56.7% of net profit [9] - The company operates eight hospitals, but the financial performance of the majority is underwhelming, with significant losses reported from some facilities [9][10] - The market expectations for Sanbo Brain Science are high, as investors anticipate the replication of the success of its flagship hospital across its other facilities, highlighting a conflict between the fast-paced capital market and the slow-cycle nature of healthcare services [10] Group 4: Industry Context - The broader non-consumer private healthcare sector is facing scrutiny, with various listed companies reporting mixed financial results, indicating that being publicly listed does not guarantee success [13][14] - The number of registered private healthcare enterprises has been declining over the past five years, reflecting a cautious outlook on the industry [14] - Regulatory pressures, particularly from the National Medical Insurance Administration, have intensified, with several cases of fraud being prosecuted, further complicating the operational landscape for private healthcare providers [14]

华夏时报（www.chinatimes.net.cn）记者 于娜 北京报道 "我们医院目前正常接诊，没有变化。"北京三博脑科医院的一位内部人员告诉《华夏时报》记者。对于董事长张 阳被留置、立案调查一事给公司经营及控制权带来的影响等问题，《华夏时报》记者联系采访三博脑科，截至发 稿未收到回复。 民营医院大佬"落马" 公开资料显示，张阳于1965年10月出生，高级工商管理专业，硕士研究生学历。2003年，张阳与北京天坛医院三 位博士生导师共同创立了三博脑科。 三博脑科注册地为北京市海淀区，主要从事以神经专科为特色的临床医疗服务，主要产品包括医疗服务、药品、 供应链、其他业务。目前，三博脑科在北京、重庆、昆明、福建、成都和河南共运营了8家医院。 张阳于2004年至2025年3月，任三博脑科总经理；2014年至今，任三博脑科董事长。同时，张阳担任中国非公立医 疗机构协会副会长、中国医院协会民营医院管理分会副会长、北京市非公立医疗机构协会终身名誉会长。 据2024年年报披露，张阳直接持有公司股份10.59%，与于春江、栾国明、石祥恩为一致行动人，构成对公司的共 同控制。公司2023年4月27日公告的《招股说明书》披露了 ...

Group 1 - The core viewpoint of the article highlights the performance and market position of Sanbo Brain Science, noting its significant growth in revenue and net profit, alongside a high PE ratio compared to industry averages [1] - As of April 1, Sanbo Brain Science's stock closed at 49.29 yuan, with a PE ratio of 92.60 and a total market capitalization of 10.153 billion yuan [1] - The company ranks 37th in the medical services industry, which has an average PE ratio of 52.86 and a median of 49.90 [1] Group 2 - Sanbo Brain Science specializes in clinical medical services in neurology, including neurosurgery, neurointervention, and neuro-oncology treatments [1] - The company has a strong team of medical experts, which has led to a high volume of complex neurosurgeries, with 80% classified as the most difficult level [1] - For the third quarter of 2024, Sanbo Brain Science reported a revenue of 1.059 billion yuan, a year-on-year increase of 9.83%, and a net profit of 105 million yuan, reflecting a 42.93% increase [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 三博脑科医院管理集团股份有限公司（以下简称"公司"）于 2024 年 4 月 17 日召开第三届董事会第四次会议，审议通过了《关于回购公司股份方案的议案》， 拟使用不低于 8,000 万元（含本数）且不超过 16,000 万元（含本数）的自有资金 以集中竞价交易方式回购公司已发行的人民币普通股（A 股），并在未来适宜时 机将回购股份用于股权激励或员工持股计划。因公司实施 2023 年年度权益分派 方案，公司对本次回购价格上限进行了调整，由 90 元/股调整为 69.16 元/股。在 回购价格不超过 69.16 元/股（含本数）的条件下，按照本次回购资金总额上限测 算，回购数量约为 2,313,475 股，约占公司总股本的 1.12%；按照本次回购资金 总额下限测算，回购数量约为 1,156,737 股，约占公司总股本的 0.56%。本次回 购实施期限自董事会审议通过本次回购股份方案之日起不超过 12 个月。具体内 容详见公司分别于 2024 年 4 月 19 日、4 月 25 日、6 月 28 日在巨潮资讯网 （ ...

三博脑科医院管理集团股份有限公司 首次公开发行股票并在创业板上市招股说明书 创业板投资者风险提示：本次股票发行后拟在创业板市场上市，该市场具有较高 的投资风险。创业板公司具有创新投入大、新旧产业融合成功与否存在不确定性、 尚处于成长期、经营风险高、业绩不稳定、退市风险高等特点，投资者面临较大 的市场风险。投资者应充分了解创业板市场的投资风险及本公司所披露的风险因 素，审慎作出投资决定。 三博脑科医院管理集团股份有限公司 Sanbo Hospital Management Group Limited （北京市海淀区香山一棵松 50 号 23 号楼 105 室） 首次公开发行股票并在创业板上市 招股说明书 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 三博脑科医院管理集团股份有限公司 首次公开发行股票并在创业板上市招股说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对注册 申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行 人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之 相反的声明均属虚假不实陈述。 根据《证券法》的规定，股 ...

三博脑科医院管理集团股份有限公司 首次公开发行股票并在创业板上市 发行公告及投资风险特别公告之更正公告 本公司于 2023年 4 月 20 日公告的《三博脑科医院管理集团股份有限公司首 次公开发行股票并在创业板上市发行公告》(以下简称"《发行公告》")及《三 博脑科医院管理集团股份有限公司首次公开发行股票并在创业板上市投资风险 特别公告》(以下简称"《投资风险特别公告》")中的部分内容有误,现就该 部分内容予以更正如下: 一、《发行公告》中"重要提示" 原内容为: "3、本次发行的初步询价工作已于 2023年 4 月 17 日(T-4 日)完成。发 行人和保荐人(主承销商)根据初步询价结果,并综合考虑发行人所处行业、同 行业上市公司估值水平、市场情况、募集资金需求及承销风险等因素,协商确定 本次发行价格为 29.60 元/股,网下不再进行累计投标。 发行价格 26.90 元/股对应的发行人 2022 年市盈率为: (1) 55.75 倍(每股收益按照 2022年度经会计师事务所遵照中国会计准则 审计的扣除非经常性损益前归属于母公司股东净利润除以本次发行前总股本计 算): (2) 67.55 倍(每股收益按照 ...

三博脑科医院管理集团股份有限公司 首次公开发行股票并在创业板上市招股意向书 创业板投资者风险提示：本次股票发行后拟在创业板市场上市，该市场具有较高 的投资风险。创业板公司具有创新投入大、新旧产业融合成功与否存在不确定性、 尚处于成长期、经营风险高、业绩不稳定、退市风险高等特点，投资者面临较大 的市场风险。投资者应充分了解创业板市场的投资风险及本公司所披露的风险因 素，审慎作出投资决定。 三博脑科医院管理集团股份有限公司 Sanbo Hospital Management Group Limited （北京市海淀区香山一棵松 50 号 23 号楼 105 室） 首次公开发行股票并在创业板上市 招股意向书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 三博脑科医院管理集团股份有限公司 首次公开发行股票并在创业板上市招股意向书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对注册 申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行 人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之 相反的声明均属虚假不实陈述。 根据 ...

三博脑科医院管理集团股份有限公司 审计报告及财务报表 2020 年度至 2022 年度 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.qxx.cn 三博脑科医院管理集团股份有限公司 审计报告及财务报表 (2020年1月1日 至 2022年12月31日止) | | 目录 | 页次 | | --- | --- | --- | | | 审计报告 | 1-4 | | | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-14 | | 11 Í | 财务报表附注 | 1-131 | [信会计师事务所(特殊普通合 CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANT 审计报告 信会师报字[2023]第 ZB10069 号 三博脑科医院管理集团股份有限公司全体股东: 一、审计意见 我们审计了三博脑科医院管理集团股份有限公司(以下简称三博 脑科)财务报表 ...